With the exception of tumor burden, anti-BCMA CAR T-cell activity did not correlate with any other biological factor intrinsic to multiple myeloma primary cells, such as expression of CD38, CD138, CD56, or CD45. Here, TNFRSF17 is linked to plasma cell myeloma.